NEW YORK (GenomeWeb) – The American Society of Clinical Oncology and precision medicine firm Tempus have agreed to work together in support of ASCO's Targeted Agent and Profiling Utilization (TAPUR) Study.
Under the agreement, clinicians who order the company's 596-gene Tempus xT assay will now receive a report that has been "optimized for TAPUR participation" with a specific summary of the genomic alterations targeted by study drugs. This will hopefully help clinical sites using Tempus' assay more quickly identify and screen patients who may be eligible for the trial.
TAPUR is a prospective, non-randomized clinical trial measuring the safety and efficacy of multiple US Food and Drug Administration-approved, molecularly targeted drugs in advanced patients who test positive for a target biomarker via a test performed by a CLIA-certified, CAP-accredited lab. To date, more than 1,700 participants have consented to participate, and more than 1,220 have been treated with a TAPUR study drug, according to ASCO.
"One of the goals of Tempus is to gather as much information as possible regarding efficacy of targeted therapies in specific clinical situations and we are pleased to offer this report to support the goals of the TAPUR study," Tempus Chief Medical officer Gary Palmer said in a statement.
"The optimized Tempus report will help TAPUR clinical sites determine who is eligible in a more expedited manner," added ASCO's Richard Schilsky, principle investigator of the TAPUR Study.